Dr. Ryan T. Pitman, M.D.
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
615 S New Ballas Rd Ste Y-g230
Saint Louis, MO 63141
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2013
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
MO license 2025029054 · IN license 01082129A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $195 in total to this clinician.
| Genzyme Corporation | $58.78 |
|---|---|
| Evoendo, Inc | $50.59 |
| Regeneron Healthcare Solutions, Inc. | $36.10 |
| Mirum Pharmaceuticals, Inc. | $24.62 |
| Acadia Pharmaceuticals Inc | $24.59 |
| Food and Beverage | $195 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $29,469 in research payments for these studies, mostly to the institutions running them.
- A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age
AstraZeneca Ab - Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals, Inc. · Completed · NCT04394351
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.